Survivin as Predictive Biomarker for RA (SurviPred)

V

Vastra Gotaland Region

Status

Enrolling

Conditions

Joint Pain
Arthralgia
Rheumatoid Arthritis

Study type

Observational

Funder types

Other

Identifiers

NCT03444623
Survivin rutin

Details and patient eligibility

About

Purpose: to examine the possibility of using the onco-protein survivin as a predictive biomarker for identifying individuals at risk of developing rheumatoid arthritis within a cohort of patients seeking treatment for joint pain/stiffness. Secondly, to study survivin as a prognostic marker for joint destruction, refractory and highly active disease in patients with established RA.

Full description

The study will analyse survivin levels in a non-selected material within a cohort of patients seeking help at their primary health care for joint pain, stiffness, swelling etc. Patients presenting with such symptoms (not explained by injury or other factors) are suspected to have an arthritic condition such as RA, and are routinely tested for presence of autoantibodies RF and ACPA. In this observational study we add measurement for survivin to the blood analyses of these patients. Information about patients expressing high levels of survivin will be reported to the referring doctor at the primary health care, and for patients not previously having been examined by a rheumatologist this will be offered. The study will be performed at Sahlgrenska university hospital Gothenburg and Umeå university hospital.

Enrollment

6,000 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients seeking treatment at the primary health care for problems with their joints (pain, stiffness).

Exclusion criteria

Patients diagnosed with RA

Trial contacts and locations

1

Loading...

Central trial contact

Maria Bokarewa, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems